| [1] |
刘哲, 杨琳, 胡雪华, 等. 2011—2020年中国前列腺癌死亡趋势分析及2021—2030年变化趋势预测[J]. 中国肿瘤, 2025, 34(3):171-177.
|
|
Liu Z, Yang L, Hu X H, et al. Trend of prostate cancer mortality in China from 2011 to 2020 and prediction from 2021 to 2030[J]. China Cancer, 2025, 34(3):171-177. doi:10.11735/j.issn.1004-0242.2025.03.A002.
|
| [2] |
吴琪, 范伯男, 李岩. 2022全球癌症统计报告分析解读:中国与世界癌症疾病负担与流行趋势[J]. 诊断学理论与实践, 2025, 24(2):135-145.
|
|
Wu Q, Fan B N, Li Y. Analysis and interpretation of the 2022 Global Cancer Statistics Report:cancer burden and epidemiological trends in China and the world[J]. Journal of Diagnostics Concepts & Practice, 2025, 24(2):135-145. doi:10.16150/j.1671-2870.2025.02.004.
|
| [3] |
Raychaudhuri R, Lin D W, Montgomery R B. Prostate cancer:a review[J]. JAMA, 2025, 333(16):1433-1446. doi:10.1001/jama.2025.0228.
|
| [4] |
张美慧, 程华, 宁浩勇. 前列腺癌早期筛查方法研究进展[J]. 中华男科学杂志, 2025, 31(8):737-741.
|
|
Zhang M H, Cheng H, Ning H Y. Research progress on screening methods for early prostate cancer[J]. National Journal of Andrology, 2025, 31(8):737-741. doi:10.13263/j.cnki.nja.2025.08.012.
|
| [5] |
陶逸然, 余佳倩, 蒋聿瑛, 等. 基于PSA的前列腺癌筛查临床特征与分层干预研究:单中心经验[J]. 临床泌尿外科杂志, 2025, 40(6):529-534.
|
|
Tao Y R, Yu J Q, Jiang Y Y, et al. Clinical characteristics of PSA-based prostate cancer screening and stratified intervention study:single-center experience[J]. Journal of Clinical Urology, 2025, 40(6):529-534. doi:10.13201/j.issn.1001-1420.2025.06.010.
|
| [6] |
Zhang T, Wang Y, Inuzuka H, et al. Necroptosis pathways in tumorigenesis[J]. Semin Cancer Biol, 2022, 86(Pt 3):32-40. doi:10.1016/j.semcancer.2022.07.007.
|
| [7] |
Gong Y, Fan Z, Luo G, et al. The role of necroptosis in cancer biology and therapy[J]. Mol Cancer, 2019, 18(1):100. doi:10.1186/s12943-019-1029-8.
|
| [8] |
Yin J, Yu Y, Huang X, et al. Necroptosis in immunity,tissue homeostasis, and cancer[J]. Curr Opin Immunol, 2024, 89:102455. doi:10.1016/j.coi.2024.102455.
|
| [9] |
Li X Y, You J X, Zhang L Y, et al. A novel model based on necroptosis-related genes for predicting prognosis of patients with prostate adenocarcinoma[J]. Front Bioeng Biotechnol, 2021, 9:814813. doi:10.3389/fbioe.2021.814813.
|
| [10] |
Beltran A, Parker L A, Moral-Pélaez I, et al. Overdiagnosis for screen-detected prostate cancer incorporating patient comorbidities[J]. Eur J Public Health, 2024, 34(Supplement 3):ckae144.1304. doi:10.1093/eurpub/ckae144.1304.
|
| [11] |
Yan J, Wan P, Choksi S, et al. Necroptosis and tumor progression[J]. Trends Cancer, 2022, 8(1):21-27. doi:10.1016/j.trecan.2021.09.003.
|
| [12] |
Venkadakrishnan V B, Presser A G, Singh R, et al. Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes[J]. Nat Commun, 2024, 15(1):6779. doi:10.1038/s41467-024-51156-5.
|
| [13] |
Singh K B, Kim S H, Hahm E R, et al. Prostate cancer chemoprevention by sulforaphane in a preclinical mouse model is associated with inhibition of fatty acid metabolism[J]. Carcinogenesis, 2018, 39(6):826-837. doi:10.1093/carcin/bgy051.
|
| [14] |
Liu S, Chai T, Garcia-Marques F, et al. UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas[J]. Cell Rep Med, 2024, 5(2):101381. doi:10.1016/j.xcrm.2023.101381.
|
| [15] |
Pacheco-Castillo N C, Gómez-Montalvo J, Olivares-Illana V, et al. Inorganic arsenic induces elevated p53 levels with altered functionality impacting the expression of Toll-like receptor 3 and other target genes in immortalized prostate epithelial cells[J]. Int J Mol Sci, 2025, 26(9):4253. doi:10.3390/ijms26094253.
|
| [16] |
Ok Atilgan A, Özdemir B H, Yilmaz Akçay E, et al. Association between focal adhesion kinase and matrix metalloproteinase-9 expression in prostate adenocarcinoma and their influence on the progression of prostatic adenocarcinoma[J]. Ann Diagn Pathol, 2020, 45:151480. doi:10.1016/j.anndiagpath.2020.151480.
|
| [17] |
Li Y, He Y, Butler W, et al. Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer[J]. Sci Transl Med, 2019, 11(521):eaax0428. doi:10.1126/scitranslmed.aax0428.
|
| [18] |
Yoshinouchi S, Karouji K, Tominari T, et al. Prostate cancer expressing membrane-bound TGF-α induces bone formation mediated by the autocrine effect of prostaglandin E2 in osteoblasts[J]. Biochem Biophys Res Commun, 2023, 644:40-48. doi:10.1016/j.bbrc.2022.11.050.
|
| [19] |
Vermot A, Petit-Härtlein I, Smith S, et al. NADPH oxidases(NOX):an overview from discovery,molecular mechanisms to physiology and pathology[J]. Antioxidants (Basel), 2021, 10(6):890. doi:10.3390/antiox10060890.
|
| [20] |
Hamasaki T, Inatomi H, Katoh T, et al. N-acetyltransferase-2 gene polymorphism as a possible biomarker for prostate cancer in Japanese men[J]. Int J Urol, 2003, 10(3):167-173. doi:10.1046/j.1442-2042.2003.00586.x.
|
| [21] |
路旭东. MRI弥散加权成像联合血清PSA对外周带前列腺癌的诊断价值[J]. 影像研究与医学应用, 2025, 9(21):49-51.
|
|
Lu X D. Diagnostic value of diffusion-weighted MRI combined with serum PSA for peripheral zone prostate cancer[J]. Journal of Imaging Research and Medical Applications, 2025, 9(21):49-51. doi:10.20267/j.issn.2096-3807.2025.21.014.
|
| [22] |
Wang T H, Lee C Y, Lee T Y, et al. Biomarker identification through multiomics data analysis of prostate cancer prognostication using a deep learning model and similarity network fusion[J]. Cancers (Basel), 2021, 13(11):2528. doi:10.3390/cancers13112528.
|
| [23] |
张玥, 汪越, 魏禹焘, 等. 抑制SHP2和FGFR2调控RAS/ERK及PI3K/AKT通路治疗FGFR2融合胃癌[J]. 中国肿瘤临床, 2024, 51(14):703-709.
|
|
Zhang Y, Wang Y, Wei Y T, et al. Co-inhibiting SHP2 and FGFR2 to treat FGFR2-fused gastric cancer by regulating RAS/ERK and PI3K/AKT signaling pathways[J]. Chinese Journal of Clinical Oncology, 2024, 51(14):703-709. doi:10.12354/j.issn.1000-8179.2024.20240715.
|
| [24] |
Warzecha C C, Sato T K, Nabet B, et al. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing[J]. Mol Cell, 2009, 33(5):591-601. doi:10.1016/j.molcel.2009.01.025.
|